The anti-melanoma differentiation-associated gene 5 (MDA-5) antibody is a marker of clinically amyopathic dermatomyositis (CADM) and rapidly progressive interstitial lung disease (ILD) with acute respiratory failure. A 35-year-old woman with cervical cancer showed Gottron's papules, severe hypoxemia, and diffuse ground-glass opacities on chest computed tomography. She was diagnosed with rapidly...

The presence of anti-MDA5 antibodies in serum represents an important biomarker in the diagnosis and prediction of prognosis for patients with idiopathic inflammatory myopathies (IIMs). Due to conflicting results that have been reported regarding the detection of anti-MDA5 antibodies, the goal of this study was to assess a potential association between the presence of anti-MDA5 antibodies and d...

Anti-MDA5 antibody-positive patients with clinically amyopathic dermatomyositis (CADM) are at high risk of developing rapidly progressive interstitial lung disease (ILD), which is associated with a high mortality rate. Approximately half of the patients with ILD recover; however, the long-term clinical course of these patients has not been fully reported and is not completely understood. This r...

Clinically amyopathic dermatomyositis (CADM) can be challenging to diagnose due clinicopathologic overlap with other skin rashes and potentially subtle examination findings in patients darker skin. The degree which a patient’s color impacts clinical presentation of CADM, time diagnosis, screening for comorbidities such as malignancy interstitial lung disease (ILD) has not been studied in-depth ...

Clinically amyopathic dermatomyositis (CADM), described almost 50 years ago, is defined on the basis of still not validated criteria and characterized by skin findings almost without muscle weakness. Autoantibodies directed against the cytosolic pathogen sensor MDA5 (CADM 140) can mark this subtype of dermatomyositis which has been reported to associate, in particular ethnic groups, with severe...

Objectives: To correlate the precise specificity of autoantibodies in Japanese dermatomyositis (DM) patients with their clinical phenotypes. Methods: Serum samples from 94 adult DM patients (67 with classical DM and 27 with clinically amyopathic dermatomyositis, CADM) were screened for autoantibodies using immunoprecipitation assays. Patients with antibodies against aminoacyl transfer RNA synth...

To evaluate the efficacy of pirfenidone in patients with rapidly progressive interstitial lung disease (RPILD) related to clinically amyopathic dermatomyositis (CADM), we conducted an open-label, prospective study with matched retrospective controls. Thirty patients diagnosed with CADM-RPILD with a disease duration <6 months at Renji Hospital South Campus from June 2014 to November 2015 were pr...

autoantibodies to cellular constituents are useful biomarkers associated with a certain diagnosis or clinical manifestations or both. Autoantibodies in polymyositis/ dermatomyositis (PM/DM) have been actively studied in recent years, and several myositis-specifi c antibodies (MSAs) have been newly described. In the previous issue of Arthritis Research & Th erapy, Muro and colleagues [1] reporte...

Abstract This study makes the case for a new scientific logic of routine animal health care in industrial farming Europe. We argue that social regime underpinning research and development on chronic disease management (CADM) Europe stifles innovation sustains productivist model husbandry facilitates maintains diseases rather than eliminating them. Drawing documentary analysis qualitative interv...